ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $339,174 | -22.3% | 9,514 | +0.6% | 0.01% | -16.7% |
| Q2 2023 | $436,436 | +42.5% | 9,461 | +23.9% | 0.01% | +50.0% |
| Q1 2023 | $306,244 | -14.3% | 7,637 | -1.0% | 0.00% | -33.3% |
| Q4 2022 | $357,436 | +35.9% | 7,715 | +21.3% | 0.01% | +20.0% |
| Q3 2022 | $263,000 | -31.7% | 6,361 | -1.3% | 0.01% | -37.5% |
| Q2 2022 | $385,000 | -7.0% | 6,446 | +13.2% | 0.01% | +14.3% |
| Q1 2022 | $414,000 | -13.9% | 5,696 | -0.4% | 0.01% | -12.5% |
| Q4 2021 | $481,000 | -5.1% | 5,718 | +1.7% | 0.01% | -20.0% |
| Q3 2021 | $507,000 | -8.2% | 5,621 | -3.0% | 0.01% | 0.0% |
| Q2 2021 | $552,000 | +117.3% | 5,794 | +215.2% | 0.01% | +66.7% |
| Q4 2020 | $254,000 | +23.9% | 1,838 | -30.0% | 0.01% | +20.0% |
| Q2 2020 | $205,000 | – | 2,627 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |